Cover Image
市場調查報告書

全球藥物安全檢測 (PV) 市場:分析及預測

Global Pharmacovigilance (PV) Market: Analysis & Forecast 2016-2022

出版商 BIS Research 商品編碼 372635
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球藥物安全檢測 (PV) 市場:分析及預測 Global Pharmacovigilance (PV) Market: Analysis & Forecast 2016-2022
出版日期: 2016年09月30日 內容資訊: 英文 219 Pages
簡介

本報告提供全球藥物安全檢測市場相關調查,市場概要與產業趨勢,今後的預測,各地區,各檢驗方法趨勢,及產業的主要參與企業簡介彙整。

摘要整理

第1章 調查範圍和調查方法

第2章 市場概要

  • 藥物安全檢測的需求
  • 藥物安全檢測的優點
  • 藥物安全檢測的報告
  • 藥物安全檢測服務類型
  • 外包的藥價決策模式
  • 藥物安全檢測的應用

第3章 市場趨勢

  • 推動市場的要素
  • 市場課題
  • 市場機會

第4章 競爭趨勢

  • 主要市場的發展與策略
  • 產業的魅力度

第5章 產業分析

  • 專利分析
  • 國際集團和機關
  • 專利
  • 價值鏈分析

第6章 各臨床實驗世界的藥物安全檢測市場分析與預測

  • 市場概要
  • 前臨床
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第7章 服務供應商市場分析與預測

  • 市場概要
  • 內部藥物安全檢測
  • 外包藥物安全檢測

第8章 各地區市場分析與預測

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第9章 企業簡介

圖表

目錄
Product Code: MD12

The pharmacovigilance market is expected to reach a market size of $8.23 billion by 2022. Stringent compliance with drug safety regulations and increasing incidents of ADRs are acting as key drivers for the growth of this market.

Medicinal products have changed the way in which diseases are managed and controlled in the current era of medical technology. Regardless of the benefits, Adverse Drug Reactions (ADRs) continue to increase leading to illness, disability and even death of the patients. Globally, ADRs are one of the leading causes of mortality. Monitoring and evaluation of drug safety becomes vital in order to enhance public health, which requires a pharmacovigilance (PV) system in place. Globalization and free trade explosion have changed the way individuals today access medicinal products. Therefore, effective collaboration is required between pharmaceutical organizations and the key pharmacovigilance players in order to minimize the risks associated with the use of medicines.

The report titled “Global Pharmacovigilance Market” provides an in-depth analysis of the key development strategies and market trend dynamics which includes drivers, challenges and opportunities prevailing in the pharmacovigilance market. Key regulatory bodies have also been considered in the report because of the compliance requirements with drug safety regulations. Moreover, value chain analysis, consortiums and patents have also been included in the report. Porter's five forces analysis has also been examined for deeper understanding of the nature of competition prevailing in the market

The pharmacovigilance market estimation and Full Time Equivalent (FTE) pricing analysis for case processing has been built on detailed assumptions. The market has been estimated based on clinical trials, service provider type and geography.

The report profiles 43 organizations on the basis of service providers working for different clinical trials across different geographies.

Key questions answered in the report:

  • What are the key drivers, challenges and opportunities for the global pharmacovigilance market?
  • What kind of development strategies do pharmacovigilance players leverage on?
  • What is the Cost/FTE/hr pricing analysis related to case processing for specific market players?
  • Who are the major, medium and minor outsourcing case processors market players?
  • What are the clinical trial phases and their pharmacovigilance market size?
  • What types of service provider prevail in the PV market with their market share and size?
  • Which region is currently dominating the pharmacovigilance market and the market size by different geography?
  • What is the case processing graph for specific pharmacovigilance market players for the past five years (2011-2015)?

Table of Contents

Executive summary

1. Research Scope and Methodology

  • 1.1. Scope of the Report
  • 1.2. The Global Pharmacovigilance Market Research Methodology
    • 1.2.1. Research Methodology for Case Processing Cost FTE/HR Calculation
    • 1.2.2. Primary Data Sources
    • 1.2.3. Secondary Data Sources
  • 1.3. Assumptions and Limitations for Market Estimation and FTE Pricing
    • 1.3.1. Assumptions
    • 1.3.2. Limitations

2. Market Overview

  • 2.1. Need for Pharmacovigilance
  • 2.2. Benefits of Pharmacovigilance
  • 2.3. Reporting in Pharmacovigilance
  • 2.4. Pharmacovigilance Service Types
  • 2.5. Outsourcing Pricing Delivery Models
  • 2.6. Applications for Pharmacovigilance

3. Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in Drug Consumption due to rise in Chronic Illness
    • 3.1.2. Evolving Drug Safety Regulations and Safety Issues
    • 3.1.3. High Data Volumes of Adverse Events
    • 3.1.4. Role of Emerging Markets in Driving Pharmacovigilance
    • 3.1.5. Emergence of Social Media and Digital Health
  • 3.2. Challenges
    • 3.2.1. Globalization
    • 3.2.2. Web Based Sales and Information
    • 3.2.3. Broader Safety Concerns
    • 3.2.4. Public Health versus Pharmaceutical Industry Economic Growth
    • 3.2.5. Data Privacy
  • 3.3. Opportunities in Pharmacovigilance
    • 3.3.1. Proactive Pharmacovigilance
    • 3.3.2. Personalized Medicines
    • 3.3.3. Innovations and Advancements in Technologies
    • 3.3.4. Database Analytics

4. Competitive Landscape

  • 4.1. Key Development Strategies
    • 4.1.1. Mergers and Acquisitions
    • 4.1.2. Product Development and Launches
    • 4.1.3. Partnerships, Collaborations and Agreements
    • 4.1.4. Business Expansions
    • 4.1.5. Awards and Recognitions
  • 4.2. Industry Attractiveness

5. Industry Analysis

  • 5.1. Regulatory Agencies
  • 5.2. Consortiums and Agencies
  • 5.3. Patents
  • 5.4. Value Chain Analysis

6. Global Pharmacovigilance Market Analysis & Forecast by Clinical Trials Insights

  • 6.1. Market Overview
  • 6.2. Preclinical Trial
    • 6.2.1. Market Overview
  • 6.3. Phase I Clinical Trial
    • 6.3.1. Market Overview
  • 6.4. Phase II Clinical Trial
    • 6.4.1. Market Overview
  • 6.5. Phase III Clinical Trial
    • 6.5.1. Market Overview
  • 6.6. Phase IV Clinical Trial
    • 6.6.1. Market Overview

7. Global Pharmacovigilance Market Analysis & Forecast by Service Provider Type

  • 7.1. Market Overview
  • 7.2. In-House Pharmacovigilance
    • 7.2.1. Market Overview
  • 7.3. Outsourcing Pharmacovigilance
    • 7.3.1. Market Overview

8. Global Pharmacovigilance Market Analysis & Forecast by Geography

  • 8.1. Market Overview
  • 8.2. North America
    • 8.2.1. Market Overview
    • 8.2.2. U.S.
    • 8.2.3. Canada
  • 8.3. Europe
    • 8.3.1. Market Overview
    • 8.3.2. United Kingdom (U.K.)
    • 8.3.3. Germany
    • 8.3.4. France
    • 8.3.5. Italy
    • 8.3.6. Spain
    • 8.3.7. Others
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Market Overview
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. China
    • 8.4.5. Korea
    • 8.4.6. Others
  • 8.5. Rest of the World (RoW)
    • 8.5.1. Market Overview

9. Company Profiles

  • 9.1. PrimeVigilance
    • 9.1.1. Company Overview
    • 9.1.2. Global Footprint
    • 9.1.3. PV Case Processing Snapshot
  • 9.2. Accenture
    • 9.2.1. Company Overview
    • 9.2.2. Global Footprint
    • 9.2.3. PV Case Processing Snapshot
  • 9.3. 4C Pharma Solutions
    • 9.3.1. Company Overview
    • 9.3.2. Global Footprint
    • 9.3.3. PV Case Processing Snapshot
  • 9.4. PharSafer Associates
    • 9.4.1. Company Overview
    • 9.4.2. Global Footprint
    • 9.4.3. PV Case Processing Snapshot
  • 9.5. Clinquest
    • 9.5.1. Company Overview
    • 9.5.2. Global Footprint
    • 9.5.3. PV Case Processing Snapshot
  • 9.6. iMEDGlobal Corporation
    • 9.6.1. Company Overview
    • 9.6.2. Global Footprint
    • 9.6.3. PV Case Processing Snapshot
  • 9.7. InVentiv Health Clinical
    • 9.7.1. Company Overview
    • 9.7.2. Global Footprint
    • 9.7.3. PV Case Processing Snapshot
  • 9.8. United BioSource Corporation (UBC)
    • 9.8.1. Company Overview
    • 9.8.2. Global Footprint
    • 9.8.3. PV Case Processing Snapshot
  • 9.9. Parexel
    • 9.9.1. Company Overview
    • 9.9.2. Global Footprint
    • 9.9.3. PV Case Processing Snapshot
  • 9.10. PPD
    • 9.10.1. Company Overview
    • 9.10.2. Global Footprint
    • 9.10.3. PV Case Processing Snapshot
  • 9.11. Apcer LifeSciences
    • 9.11.1. Company Overview
    • 9.11.2. Global Footprint
    • 9.11.3. PV Case Processing Snapshot
  • 9.12. iSafety Systems
    • 9.12.1. Company Overview
    • 9.12.2. Global Footprint
    • 9.12.3. PV Case Processing Snapshot
  • 9.13. 4G Pharmacovigilance
    • 9.13.1. Company Overview
    • 9.13.2. Global Footprint
    • 9.13.3. PV Case Processing Snapshot
  • 9.14. Redline Pharmacovigilance
    • 9.14.1. Company Overview
    • 9.14.2. Global Footprint
    • 9.14.3. PV Case Processing Snapshot
  • 9.15. Oviya Medsafe
    • 9.15.1. Company Overview
    • 9.15.2. Global Footprint
    • 9.15.3. PV Case Processing Snapshot
  • 9.16. ProductLife Group (PLG)
    • 9.16.1. Company Overview
    • 9.16.2. Global Footprint
    • 9.16.3. PV Case Processing Snapshot
  • 9.17. Lindeq
    • 9.17.1. Company Overview
    • 9.17.2. Global Footprint
    • 9.17.3. PV Case Processing Snapshot
  • 9.18. Voisin Consulting LifeSciences (VCLS)
    • 9.18.1. Company Overview
    • 9.18.2. Global Footprint
    • 9.18.3. PV Case Processing Snapshot
  • 9.19. Ecron Acunova
    • 9.19.1. Company Overview
    • 9.19.2. Global Footprint
    • 9.19.3. PV Case Processing Snapshot
  • 9.20. Cmed Group
    • 9.20.1. Company Overview
    • 9.20.2. Global Footprint
    • 9.20.3. PV Case Processing Snapshot
  • 9.21. Regulis Consulting
    • 9.21.1. Company Overview
    • 9.21.2. Global Footprint
    • 9.21.3. PV Case Processing Snapshot
  • 9.22. NDA Group
    • 9.22.1. Company Overview
    • 9.22.2. Global Footprint
  • 9.23. Synowledge
    • 9.23.1. Company Overview
    • 9.23.2. Global Footprint
    • 9.23.3. PV Case Processing Snapshot
  • 9.24. Prosar
    • 9.24.1. Company Overview
    • 9.24.2. Global Footprint
    • 9.24.3. PV Case Processing Snapshot
  • 9.25. Premier Research
    • 9.25.1. Company Overview
    • 9.25.2. Global Footprint
    • 9.25.3. PV Case Processing Snapshot
  • 9.26. Medpace
    • 9.26.1. Company Overview
    • 9.26.2. Global Footprint
    • 9.26.3. PV Case Processing Snapshot
  • 9.27. Vigilex
    • 9.27.1. Company Overview
    • 9.27.2. Global Footprint
    • 9.27.3. PV Case Processing Snapshot
  • 9.28. Sciformix
    • 9.28.1. Company Overview
    • 9.28.2. Global Footprint
    • 9.28.3. PV Case Processing Snapshot
  • 9.29. Symogen
    • 9.29.1. Company Overview
    • 9.29.2. Global Footprint
    • 9.29.3. PV Case Processing Snapshot
  • 9.30. RxLogix
    • 9.30.1. Company Overview
    • 9.30.2. Global Footprint
    • 9.30.3. PV Case Processing Snapshot
  • 9.31. Drug Safety Alliance
    • 9.31.1. Company Overview
    • 9.31.2. Global Footprint
    • 9.31.3. PV Case Processing Snapshot
  • 9.32. Quintiles
    • 9.32.1. Company Overview
    • 9.32.2. Global Footprint
    • 9.32.3. PV Case Processing Snapshot
  • 9.33. Sentrx Safety Solutions
    • 9.33.1. Company Overview
    • 9.33.2. Global Footprint
    • 9.33.3. PV Case Processing Snapshot
  • 9.34. Tata Consultancy Services (TCS)
    • 9.34.1. Company Overview
    • 9.34.2. Global Footprint
    • 9.34.3. PV Case Processing Snapshot
  • 9.35. ICON plc
    • 9.35.1. Company Overview
    • 9.35.2. Global Footprint
    • 9.35.3. PV Case Processing Snapshot
  • 9.36. Covance
    • 9.36.1. Company Overview
    • 9.36.2. Global Footprint
    • 9.36.3. PV Case Processing Snapshot
  • 9.37. PRA Health Sciences
    • 9.37.1. Company Overview
    • 9.37.2. Global Footprint
    • 9.37.3. PV Case Processing Snapshot
  • 9.38. Cognizant
    • 9.38.1. Company Overview
    • 9.38.2. Global Footprint
    • 9.38.3. PV Case Processing Snapshot
  • 9.39. Bristol-Myers-Squibb
    • 9.39.1. Company Overview
    • 9.39.2. Global Footprint
  • 9.40. GlaxoSmithKline
    • 9.40.1. Company Overview
    • 9.40.2. Global Footprint
  • 9.41. Sanofi
    • 9.41.1. Company Overview
    • 9.41.2. Global Footprint
  • 9.42. Pfizer
    • 9.42.1. Company Overview
    • 9.42.2. Global Footprint
  • 9.43. Roche
    • 9.43.1. Company Overview
    • 9.43.2. Global Footprint

List of Tables

  • Table 1: Case Processing Organizations Classification
  • Table 1.1: Sample FTE/Hour Cost Calculation Sheet
  • Table 2.1: Indicators to Measure ADRs
  • Table 2.2: Detection and Prevention of Adverse Events
  • Table 4.1: Mergers in Pharmacovigilance Market (2014-16)
  • Table 4.2: Acquisitions in Pharmacovigilance Market (2014-16)
  • Table 4.3: Latest Product Launches in Pharmacovigilance Market (2013-16)
  • Table 4.4: Key Partnerships and Collaborations in Pharmacovigilance Industry (2014-16)
  • Table 4.5: Key Expansions in Pharmacovigilance Industry (2013-16)
  • Table 4.6: Awards and Recognitions to Pharmacovigilance Companies (2013-16)
  • Table 4.7: Buyers and Suppliers in Global Pharmacovigilance Market
  • Table 4.8: Key Factors considered for threat from New Entrants in Global Pharmacovigilance Market
  • Table 4.9: Key Factors Affecting Bargaining Power of Buyers in the Global Pharmacovigilance Market
  • Table 4.10: Key Factors affecting the Bargaining Power of Suppliers in the Global Pharmacovigilance Market
  • Table 4.11: Key Factors affecting threat of Substitute Products or Services in the Global Pharmacovigilance Market
  • Table 4.12: Key Factors determining Rivalry among Existing Firms in the Global Pharmacovigilance Market
  • Table 5.1: Prominent Regulatory Agencies Region wise Working for Pharmacovigilance
  • Table 5.2: List of Consortiums and Agencies active in the Pharmacovigilance Industry
  • Table 5.3: List of Patents in Pharmacovigilance Market (2014-16)
  • Table 6.1: Clinical Trial Safety Monitoring Key Stakeholders
  • Table 6.2: Key Drugs Safety Issues
  • Table 6.4: Pharmacovigilance Market by Clinical Trials Insights, 2015-2022
  • Table 6.5: Pharmacovigilance Market Value for Preclinical Trials Insight by Service Provider Type, 2015-2022
  • Table 6.6: Pharmacovigilance Market Value for Preclinical Trials Insight by Geography, 2015-2022
  • Table 6.7: Pharmacovigilance Market Value for Phase I Clinical Trials Insight by Service Provider Type, 2015-2022
  • Table 6.8: Pharmacovigilance Market Value for Phase I Clinical Trials Insight by Geography, 2015- 2022
  • Table 6.9: Pharmacovigilance Market Value for Phase II Clinical Trials Insight by Service Provider Type, 2015-2022
  • Table 6.10: Pharmacovigilance Market Value for Phase II Clinical Trials Insight by Geography, 2015-2022
  • Table 6.11: Pharmacovigilance Market Value for Phase III Clinical Trials Insight by Service Provider Type, 2015-2022
  • Table 6.12: Pharmacovigilance Market Value for Phase III Clinical Trials Insight by Geography, 2015-2022
  • Table 6.13: Pharmacovigilance Market Value for Phase IV Clinical Trials Insight by Service Provider Type, 2015-2022
  • Table 6.14: Pharmacovigilance Market Value for Phase IV Clinical Trials Insight by Geography, 2015-2022
  • Table 7.1: Pharmacovigilance Market Value by Service Provider Type, 2015-2022
  • Table 7.2: In-House Pharmacovigilance Market Value by Clinical Trials Insights, 2015-2022
  • Table 7.3: In-House Pharmacovigilance Market Value by Geography, 2015-2022
  • Table 7.4: Outsource Pharmacovigilance Market Value by Clinical Trial, 2015-2022
  • Table 7.5: Outsource Pharmacovigilance Market Value by Geography, 2015-2022
  • Table 8.1: North America Pharmacovigilance Market Value by Clinical Trials, 2015-2022
  • Table 8.2: North America Pharmacovigilance Market Value by Service Provider Type, 2015-2022
  • Table 8.3: Europe Pharmacovigilance Market Value by Clinical Trials, 2015-2022
  • Table 8.4: Europe Pharmacovigilance Market Value by Service Provider Type, 2015-2022
  • Table 8.5: APAC Pharmacovigilance Market Value by Clinical Trials, 2015-2022
  • Table 8.6: APAC Pharmacovigilance Market Value by Service Provider Type, 2015-2022
  • Table 8.7: RoW Pharmacovigilance Market Value by Clinical Trials, 2015-2022
  • Table 8.8: RoW Pharmacovigilance Market Value by Service Provider Type, 2015-2022

List of Figures

  • Figure 1: Serious Adverse Events Reported to FDA
  • Figure 2: Global Pharmacovigilance Market Size Snapshot
  • Figure 3: Global Pharmacovigilance Market by Clinical Trials Snapshot
  • Figure 4: Global Pharmacovigilance Service Provider Type Share (%), 2015 and 2022
  • Figure 5: Global Pharmacovigilance Market by Geography Snapshot
  • Figure 1.1: Global Pharmacovigilance Market Scope
  • Figure 1.2: Top Down and Bottom up Approach for Market Estimation
  • Figure 1.3: Average Cost/FTE/Region Case Processing Trend Analysis
  • Figure 2.1: Objectives of Pharmacovigilance
  • Figure 2.2: Pharmacovigilance Evolution
  • Figure 2.3: Need for Pharmacovigilance
  • Figure 2.4: ADEs Types
  • Figure 2.5: Number of Deaths due to various causes in the U.S. (2013)
  • Figure 2.6: Types of Medication Errors
  • Figure 3.1: Market Dynamics Snapshot
  • Figure 3.2: YoY growth of Adverse Events (2011-14)
  • Figure 3.3: Parameters for Safety Concerns
  • Figure 4.1: Pharmacovigilance Market Development Trends Share Analysis
  • Figure 4.2: Porter's Five Forces Analysis for Global Pharmacovigilance Market
  • Figure 5.1: Pharmacovigilance Value Chain
  • Figure 6.1: Clinical Trial Phases in Drug Development Process
  • Figure 6.2: Key Preclinical Pharmacovigilance Services
  • Figure 6.3: Phase I-IV Pharmacovigilance Services
  • Figure 6.4: Pharmacovigilance Opportunity Matrix for Clinical Trials
  • Figure 6.5: Preclinical Safety Evaluation: Considerations
  • Figure 6.6: Preclinical Safety Evaluation Elements
  • Figure 6.7: Preclinical Safety Evaluation Primary Goals
  • Figure 6.8: Key Preclinical Pharmacovigilance Services Providers
  • Figure 6.9: Phase I Clinical Trial Process
  • Figure 6.10: Phase I Data Collection Parameters
  • Figure 6.11: Key Phase I Pharmacovigilance Services Providers
  • Figure 6.12: Phase II Clinical Trial Primary Goals
  • Figure 6.13: Key Phase II Pharmacovigilance Services Providers
  • Figure 6.14: Phase III Clinical Trial Primary Goals
  • Figure 6.15: Key Phase III Pharmacovigilance Services Providers
  • Figure 6.16: Phase IV Clinical Trial Primary Goals
  • Figure 6.17: Key Phase IV Pharmacovigilance Services Providers
  • Figure 7.1: Key Benefits of Outsourcing PV Activities
  • Figure 7.2: Pharmacovigilance Opportunity Matrix for Service Provider Type
  • Figure 7.3: Key In-House Pharmacovigilance Services Providers
  • Figure 7.4: Key Outsourcing Pharmacovigilance Services Providers
  • Figure 8.1: Global PV Market Geographical Segmentation
  • Figure 8.2: Pharmacovigilance Opportunity Matrix for Different Regions
  • Figure 8.3: Pharmacovigilance Market Value Snapshot by Geography, 2015-2022
  • Figure 8.4: Evolution of FDA Pharmacovigilance Activities and Requirements
  • Figure 8.5: Key Changes in the PV Legislation of Europe
Back to Top